Company profile: Actuate Therapeutics
1.1 - Company Overview
Company description
- Provider of therapeutics and clinical research focused on elraglusib for high-impact cancers and neurodegenerative diseases, including adult and pediatric injection and oral tablet formulations for advanced, refractory solid and hematological cancers (e.g., pancreatic, metastatic melanoma, colorectal), combination regimens with chemotherapy, ongoing trials to assess efficacy and safety, and partnerships with academic and scientific organizations
Products and services
- Clinical Trials: Ongoing, multi-cancer studies evaluating elraglusib’s efficacy and safety across various cancer types, including pancreatic cancer and pediatric solid cancers
- Elraglusib Injection — Adult (Actuate-1801): An adult-targeted injectable that targets multiple molecular pathways in cancer, used in dose-escalation regimens and combination therapies specifically for pancreatic cancer
- Elraglusib Oral Tablet — Adult (Actuate-2401): An adult-specific oral formulation for advanced, refractory solid cancers, including metastatic melanoma and colorectal cancer, delivered via tablet-based administration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Actuate Therapeutics
Sevion Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery, development, and acquisition of innovative therapeutic product candidates for cancer and immunological diseases, advancing a pipeline of proprietary and partnered candidates leveraging unique antibody technology platforms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sevion Therapeutics company profile →
Advesya
HQ: France
Website
- Description: Provider of therapies for difficult-to-treat cancers, focusing on immuno-oncology and hematological malignancies, leveraging biochemistry and molecular and cellular biology expertise. Offers ADV-101, a topoisomerase I inhibitor antibody-drug conjugate targeting IL-1RAP for esophageal cancer, delivering cytotoxic agents directly to cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advesya company profile →
Amphivena Therapeutics
HQ: United States
Website
- Description: Provider of a platform of dual-function biologics in clinical-stage immuno-oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amphivena Therapeutics company profile →
Artbio
HQ: United States
Website
- Description: Provider of clinical-stage alpha radioligand medicines and enabling technologies, including AB001, a 212Pb-based radiopharmaceutical candidate for prostate cancer in Phase I/II trials; AlphaDirect technology for isolating Pb-212 to enable distributed manufacturing; and a distributed end-to-end manufacturing network to deliver therapeutic candidates rapidly and flexibly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artbio company profile →
Oric Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical treatments that target the causes of therapeutic resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oric Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Actuate Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Actuate Therapeutics
2.2 - Growth funds investing in similar companies to Actuate Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Actuate Therapeutics
4.2 - Public trading comparable groups for Actuate Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →